Patient Feedback on a Mobile Medication Adherence App for Buprenorphine and Naloxone: Closed and Open-Ended Survey on Feasibility and Acceptability

Patient Feedback on a Mobile Medication Adherence App for Buprenorphine and Naloxone: Closed and Open-Ended Survey on Feasibility and Acceptability

BackgroundOpioid use disorders impact the health and well-being of millions of Americans. Buprenorphine and naloxone (BUP and NAL) can reduce opioid overdose deaths, decrease misuse, and improve quality of life. Unfortunately, poor medication adherence is a primary barrier to...

Full description

Bibliographic Details
Main Authors:	Crystal L Smith, Abigail Keever, Theresa Bowden, Katie Olson, Nicole Rodin, Michael G McDonell, John M Roll, Gillian Smoody, Jeff LeBrun, Andre QC Miguel, Sterling M McPherson
Format:	Article
Language:	English
Published:	JMIR Publications 2023-04-01
Series:	JMIR Formative Research
Online Access:	https://formative.jmir.org/2023/1/e40437

Similar Items

Oxybutynin treatment for buprenorphine-naloxone-induced hyperhidrosis
by: Lindsay McCormack, BA, et al.
Published: (2021-04-01)

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men
by: Hassan Ziaaddini, et al.
Published: (2018-12-01)

Reconsidering the Usefulness of Adding Naloxone to Buprenorphine
by: Christopher K. Blazes, et al.
Published: (2020-09-01)

Disparities in Emergency Department Naloxone and Buprenorphine Initiation
by: Joan Papp, et al.
Published: (2023-06-01)

Epidural Naloxone to Prevent Buprenorphine Induced PONV
by: Ashok Jadon, et al.
Published: (2008-01-01)

Development of Automated Reinforcement Management System (ARMS): Protocol for a Phase I Feasibility and Usability Study
by: Andre Miguel, et al.
Published: (2021-07-01)

Automated Reinforcement Management System: Feasibility study findings of an app-based contingency management treatment for alcohol use disorder
by: André Q. Miguel, et al.
Published: (2023-03-01)

Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market
by: Bruce, R.D., et al.
Published: (2009)

A retrospective evaluation of patients switched from buprenorphine (subutex) to the buprenorphine/naloxone combination (suboxone)
by: Vorma Helena, et al.
Published: (2008-06-01)

Guanfacine Treatment in a Patient with Intravenous Buprenorphine/Naloxone Misuse
by: Sercan Karabulut
Published: (2024-01-01)

Neonatal outcomes following in utero exposure to buprenorphine/naloxone or methadone
by: Kristen M Gawronski, et al.
Published: (2014-04-01)

A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes
by: Ingunn O. Lund, et al.
Published: (2013-01-01)

A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes
by: Ingunn O. Lund, et al.
Published: (2013-03-01)

Safety and Efficacy of Buprenorphine-Naloxone in Pregnancy: A Systematic Review of the Literature
by: Alice Ordean, et al.
Published: (2023-02-01)

Automated Reinforcement Management System (ARMS): focused phase I provider feedback
by: Crystal L. Smith, et al.
Published: (2022-03-01)

Comment on “A Comparison of Buprenorphine + Naloxone to Buprenorphine and Methadone in the Treatment of Opioid Dependence during Pregnancy: Maternal and Neonatal Outcomes”
by: Robert G. Newman M.D., M.P.H., et al.
Published: (2013-01-01)

New developments in the management of opioid dependence: focus on sublingual buprenorphine–naloxone
by: Soyka M
Published: (2015-01-01)

Management of buprenorphine/naloxone therapy in substances abuse consumers in prison: efficacy and safety
by: Felice A. Nava
Published: (2018-11-01)

Healthcare provider perspectives on emergency department-initiated buprenorphine/naloxone: a qualitative study
by: Katherin Badke, et al.
Published: (2024-02-01)

Sublingual Buprenorphine/Naloxone and Multi-Modal Management for High-Risk Chronic Pain Patients
by: Shane Kaski, et al.
Published: (2021-03-01)

Perioperative opioid requirements of patients receiving sublingual buprenorphine-naloxone: a case series
by: Yvette N. Martin, et al.
Published: (2019-05-01)

Development and implementation of a physician-pharmacist collaborative practice model for provision and management of buprenorphine/naloxone
by: Lindsay M. Mailloux, PharmD, et al.
Published: (2021-01-01)

Factors associated with frequent buprenorphine / naloxone initiation in a national survey of Canadian emergency physicians.
by: Nathalie MacKinnon, et al.
Published: (2024-01-01)

Sociodemographic and clinical characteristics of patients with long-term remission with buprenorphine / naloxone in opiate use disorder
by: Y. Kahya, et al.
Published: (2021-04-01)

Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach
by: Jennifer Rozylo, et al.
Published: (2020-01-01)

Microdose induction of buprenorphine-naloxone in a patient using high dose methadone: A case report
by: Menard Shannon PharmD, et al.
Published: (2021-11-01)

Sexual Adverse Effects and Erectile Dysfunction During Buprenorphine/Naloxone Combination Treatment for Opioid Use Disorders
by: Bestepe EE, et al.
Published: (2020-11-01)

Prevalence of Current Restless Legs Syndrome Symptoms Among Patients Treated with Buprenorphine/Naloxone for Opioid Use Disorder
by: Wipper B, et al.
Published: (2023-10-01)

Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic
by: David Dadiomov, et al.
Published: (2022-06-01)

Comparative Trial to Study the Effectiveness of Clonidine Hydrochloride and Buprenorphine-Naloxone in Opioid Withdrawal – A Hospital Based Study
by: Syed Sajad Hussain, et al.
Published: (2015-01-01)

A review of contingency management for the treatment of substance-use disorders: adaptation for underserved populations, use of experimental technologies, and personalized optimization strategies
by: McPherson SM, et al.
Published: (2018-08-01)

Variations in national availability of waivered buprenorphine prescribers by racial and ethnic composition of zip codes
by: Katherine A. Hirchak, et al.
Published: (2022-05-01)

La despensa nacional: Quinoa and the Spatial Contradictions of Peru’s Gastronomic Revolution
by: Emma McDonell
Published: (2024-03-01)

Ives, Sarah. 2017. Steeped in heritage: the racial politics of South African rooibos tea. Durham: Duke University Press. Reviewed by Emma McDonell
by: Emma McDonell
Published: (2018-03-01)

Including the isolated: Place, rurality, and the state in regional Western Australia during the COVID-19 pandemic and vaccine rollout
by: Sean McDonell, et al.
Published: (2024-06-01)

Predictors of cannabis and tobacco co-use in youth: exploring the mediating role of age at first use in the population assessment of tobacco health (PATH) study
by: Crystal Lederhos Smith, et al.
Published: (2021-06-01)

From controlled opioid substitution treatment to pharmacy delivery of buprenorphine-naloxone and to treatment in primary health care: the views of patients and personnel
by: Jouni Tourunen, et al.
Published: (2010-12-01)

From controlled opioid substitution treatment to pharmacy delivery of buprenorphine-naloxone and to treatment in primary health care: the views of patients and personnel
by: Jouni Tourunen, et al.
Published: (2010-12-01)

Comparative effectiveness of buprenorphine-naloxone versus methadone for treatment of opioid use disorder: a population-based observational study protocol in British Columbia, Canada
by: Lawrence C McCandless, et al.
Published: (2020-09-01)

Introduction to map projections /
by: McDonell, Porter W
Published: (1979)